1533 related articles for article (PubMed ID: 31320594)
41. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
[TBL] [Abstract][Full Text] [Related]
42. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
[TBL] [Abstract][Full Text] [Related]
43. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Numan Y; Abdel Rahman Z; Grenet J; Boisclair S; Bewersdorf JP; Collins C; Barth D; Fraga M; Bixby DL; Zeidan AM; Yilmaz M; Desai P; Mannis G; Deutsch YE; Abaza Y; Dinner S; Frankfurt O; Litzow M; Al-Kali A; Foran JM; Sproat LZ; Jovanovic B; Daver N; Perl AE; Altman JK
Am J Hematol; 2022 Mar; 97(3):322-328. PubMed ID: 34981560
[TBL] [Abstract][Full Text] [Related]
44. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
45. AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.
Milnerowicz S; Maszewska J; Skowera P; Stelmach M; Lejman M
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958832
[TBL] [Abstract][Full Text] [Related]
46. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
47. 4-Hydroxyphenyl Retinamide Preferentially Targets FLT3 Mutated Acute Myeloid Leukemia via ROS Induction and NF-κB Inhibition.
Zhao XY; Zhang RR; Ye Q; Qiu F; Xu HY; Wei FG; Zhang H
Curr Med Sci; 2020 Oct; 40(5):810-816. PubMed ID: 33123895
[TBL] [Abstract][Full Text] [Related]
48. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
[TBL] [Abstract][Full Text] [Related]
49. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
Kim M; Williams S
Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
[TBL] [Abstract][Full Text] [Related]
50. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
51. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
[TBL] [Abstract][Full Text] [Related]
52. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
53. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
54. Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Wang P; Zhang Y; Xiang R; Yang J; Xu Y; Deng T; Zhou W; Wang C; Xiao X; Wang S
Cancer Res; 2024 Mar; 84(6):905-918. PubMed ID: 38231480
[TBL] [Abstract][Full Text] [Related]
55. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia.
Gebru MT; Atkinson JM; Young MM; Zhang L; Tang Z; Liu Z; Lu P; Dower CM; Chen L; Annageldiyev C; Sharma A; Imamura Kawasawa Y; Zhao Z; Miller BA; Claxton DF; Wang HG
Blood; 2020 Aug; 136(9):1067-1079. PubMed ID: 32396937
[TBL] [Abstract][Full Text] [Related]
56. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
Garcia JS; Percival ME
Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
[TBL] [Abstract][Full Text] [Related]
57. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
[TBL] [Abstract][Full Text] [Related]
58. An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L.
Wang X; DeFilippis RA; Weldemichael T; Gunaganti N; Tran P; Leung YK; Shah NP; Li HY
Eur J Med Chem; 2024 Jan; 264():115977. PubMed ID: 38056299
[TBL] [Abstract][Full Text] [Related]
59. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]